RDCs (Radionuclide Drug Conjugates) are bifunctional effector molecules, consist ligands binding tightly with tumor cells, linkers, chelators, and radioisotopes functioning as both cytotoxic and imaging factors. Under the guidance of precise targeting ligand molecules, radioisotope are able to accurately kill tumor cells at a close range with high efficiency and low toxicity.
The same ligand could be "equipped" with a therapeutic radionuclide (thera) such as β-particles 177Lu or α-particles 225Ac or a diagnostic/imaging radionuclide (nostic) such as 68Ga.
Our commitment to sustainable development.